Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REPLIGEN CORPRGEN · Entity 486 | Chief Financial Officer | May 16, 2023 | May 16, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REPLIGEN CORP
Report date May 16, 2023 · Filed May 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,381 |
Reported balance
After 2023-05-16 transaction · row 1
1 source rowRow 1 · 2023-05-16 · Tax withholding · Disposed 710 · Balance 37,381 F1: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2018 Filed Mar 2, 2018 20:02 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 2,470 | $35.16 | $86,842.73 |
DisclosureSEC source: 0001140361-18-011552 · doc1.xml · nonDerivative · entry 1 Snodgres Jon · CIK 0001613498 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,974 F1 · shares: Payment of tax liability made via forfeiture of 2,470 shares of Common Stock valued at a price of $35.159 per share on February 28, 2018. Read SEC document |
| July 18, 2017 Filed Jul 20, 2017 21:25 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 345 | $41.77 | $14,410.65 |
DisclosureSEC source: 0001140361-17-028308 · doc1.xml · nonDerivative · entry 1 Snodgres Jon · CIK 0001613498 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,444 F1 · shares: Payment of tax liability made via forfeiture of 345 shares of Common Stock valued at a price of $41.77 per share on July 18, 2017. Read SEC document |
| March 17, 2017 Filed Mar 22, 2017 01:03 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $24.50 | $0.00 |
DisclosureSEC source: 0001140361-17-012886 · doc1.xml · derivative · entry 3 Snodgres Jon · CIK 0001613498 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 4,000 shares Expires 2024-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 2,000 shares vest and become exercisable on each of the following dates: 7/14/2015, 7/14/2016, 7/14/2017, 7/14/2018 and 7/14/2019. Read SEC document |
| March 17, 2017 Filed Mar 22, 2017 01:03 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 4,000 | $24.50 | $98,000.00 |
DisclosureSEC source: 0001140361-17-012886 · doc1.xml · nonDerivative · entry 2 Snodgres Jon · CIK 0001613498 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2017 Filed Mar 22, 2017 01:03 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,909 | $34.91 | $66,646.05 |
DisclosureSEC source: 0001140361-17-012886 · doc1.xml · nonDerivative · entry 1 Snodgres Jon · CIK 0001613498 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,789 Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 01:57 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 1,630 | $32.07 | $52,272.96 |
DisclosureSEC source: 0001140361-17-010118 · doc1.xml · nonDerivative · entry 2 Snodgres Jon · CIK 0001613498 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,698 F2 · shares: Payment of tax liability made via forfeiture of 1,630 shares of Common Stock valued at a weighted average price of $32.0693 per share on March 1, 2017. Read SEC document |
| February 23, 2017 Filed Mar 2, 2017 01:57 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 19,750 | $0.00 Strike: $32.32 | $0.00 |
DisclosureSEC source: 0001140361-17-010118 · doc1.xml · derivative · entry 3 Snodgres Jon · CIK 0001613498 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,750 Underlying: Common Stock · 19,750 shares Expires 2027-02-23 F3 · derivative.exercise_date: The shares vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. Read SEC document |
| February 23, 2017 Filed Mar 2, 2017 01:57 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 9,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-010118 · doc1.xml · nonDerivative · entry 1 Snodgres Jon · CIK 0001613498 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,328 F1 · shares: Mr. Snodgres was awarded 9,875 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The Restricted Stock Units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The Restricted Stock Units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| February 23, 2017 Filed Mar 22, 2017 00:22 UTC Amendment | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 19,750 | $0.00 Strike: $32.40 | $0.00 |
DisclosureSEC source: 0001140361-17-012883 · doc1.xml · derivative · entry 1 Snodgres Jon · CIK 0001613498 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,750 Underlying: Common Stock · 19,750 shares Expires 2027-02-23 F1 · derivative.exercise_date: The shares vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. Read SEC document |
| February 23, 2017 Filed May 22, 2017 21:12 UTC Amendment | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 18,165 | $0.00 Strike: $32.40 | $0.00 |
DisclosureSEC source: 0001140361-17-021770 · doc1.xml · derivative · entry 1 Snodgres Jon · CIK 0001613498 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,165 Underlying: Common Stock · 18,165 shares Expires 2027-02-23 F1 · derivative.exercise_date: The shares vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.